



703-587-4864  
aloka.srinivasan@gmail.com  
www.RAAHALLC.com  
3280 Kinross Circle,  
Herndon, VA 20171

Nov. 6, 2024

Via Electronic Submission  
Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061, HFA-305  
Rockville, MD 20852

**CITIZENS PETITION – WITHDRAWAL REQUEST**  
**RE: FDA-2024-P-3799**

Raaha LLC hereby requests to withdraw the Citizen Petition submitted on August 7 2024; assigned Docket number FDA-2024-P-3799.

The Citizen Petition was submitted pursuant to the Federal Food, Drug and Cosmetic Act (“FD&C Act”) and in accordance with 21 CFR § 10.20 and 10.30, and requested the Commissioner of Food and Drugs refrain from approving an Abbreviated New Drug Application (“ANDA”) for Prednisolone Ophthalmic Solution 1% {“Product”} without the inclusion of long-term stability studies conducted under refrigerated conditions at  $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$ .

Please advise if additional information is required in order to complete the withdrawal request.

Sincerely,

*Aloka Srinivasan*

Aloka Srinivasan, PhD/ds  
Principal and Managing Partner  
Raaha LLC  
Phone: +1-703-587-4864  
Email: aloka.srinivasan@raahallc.com  
Email (secondary): alokasrinivasan@gmail.com